
miRdetect
miRdetect is a biotechnology company founded in 2016, with the aim to revolutionise cancer diagnostics. The focus is on development, production and distribution of in-vitro diagnostics based on molecular diagnostic methods. The first product, based on the quantification of microRNA, is a blood test for the detection of testicular cancer. The high sensitivity and accuracy of the test improves the diagnosis and therapy of patients significantly and reduces the costs for the health care system. miRdetect has developed a patented platform technology, which allows the exact and reliable quantification of small amounts of genetic material in body fluids. This robust method represents the basis for the development of additional diagnostic tests.
Dr. Nina Winter, Meike Spiekermann und Dr. Arlo Radtke
miRdetect
Info & Contact
Address
Fahrenheitstraße 1
28359 Bremen
28359 Bremen
Added to portfolio
14. Dec 2018